Viral Genetics, Inc. Invited to Present New Model, Initial Findings of Lyme Disease Study at Prestigious ILADS Conference
Wednesday October 8, 3:12 pm ET
Study Group Beginning Further Research, Which it Hopes Will Unlock Mysteries, Reconcile Debate Over Lyme Treatment, Offer Answers to Other Immune Based Diseases
AZUSA, Calif.--(BUSINESS WIRE)--Viral Genetics, Inc. (Other OTC:VRAL - News), a biotechnology company that discovers and develops immune-based therapies, today announced it has been invited to present and discuss its new Lyme Disease study model and initial findings at the 2008 International Lyme & Associated Diseases Society (ILADS) Scientific Session. The study could also potentially offer answers to other immune based diseases including HIV/AIDS. In addition, the study team has begun to further explore its new model in Lyme Disease, which researchers hope will reconcile the long-standing and controversial debate in the medical community over treatment methods for Lyme Disease.
ILADS & The Annual Scientific Session
ILADS, an international nonprofit and multidisciplinary medical society, is dedicated to the diagnosis and appropriate treatment of Lyme and its associated diseases. The 2008 ILADS Scientific Session will take place in San Francisco on October 18-19th and will include some of the most esteemed physicians treating Lyme disease in the U.S. For more information on the organization and its annual conference, visit http://www.ilads. org.
"We are honored to have been invited by ILADS to share our new model and findings with our esteemed colleagues in the research and medical communities, " said Dr. M. Karen Newell, Ph.D., lead investigator of the study and a professor at the University of Colorado. "It is a validation and encourages the study team that we are moving in the right direction to potentially aid those suffering from Lyme and associated diseases."
Research in HIV/AIDS May Lead to Breakthrough in Lyme
"This study is funded by a grant earmarked specifically for Lyme research. However, our primary study of HIV/AIDS stands to benefit," Haig Keledjian, CEO of Viral Genetics.
With a commitment to discovering and developing immune-based therapies for HIV and AIDS using its thymus nuclear protein compound (TNP), Viral Genetics' new model was initially proposed solely for HIV/AIDS. However, by unraveling the mechanism of TNP, Dr. Newell identified its potential promise in other diseases including Lyme Disease.
"We've always theorized that TNP could serve as a pathway to more answers and, potentially aid in the development of more effective treatments for a variety of immune based diseases, but this is our first study outside of the HIV/AIDS arena, so we are encouraged by TNP's application to Lyme. We look forward to what further research could yield," added Newell.
The Controversy Over Treatment of Lyme Disease
Some researchers contend Lyme is driven by chronic infection and recommend patients be treated with antibiotics for the long term. Others support the hypothesis that the disease is the result of autoimmune T cell activation that occurs subsequent to the initial infection or after the infection has cleared.
"Our hope is that future findings of this study will serve as a foundation to bridge the gap between those two schools of thought, which in turn, could potentially lead to more successful treatments for chronically ill patients who suffer daily from this mysterious disease," said Dr. Steven Harris, Co-investigator, Associate Professor Stanford University.
Study Aims to Unlock Mysteries, Reconcile Debate
"Our model reconciles both the initial disease and accounts for the consequent processes that appear pathologically similar to autoimmune disease," said Dr. Newell.
The study team has made progress using basic academic research to understand molecular mechanisms that account for whether or not a person contracts Lyme Disease subsequent to the tick bite. The team is now transitioning quickly to clinical research.
"The initial data is promising and our mission is to continue making further progress in our effort to unravel the extreme complexities behind Lyme Disease. Until these scientific truths are brought forward and quickly researched collaboratively, the patients who wait daily for answers to their suffering are the victims. Our deep hope is to make a difference in their lives," said Monica Ord, SVP of corporate development and communications, Viral Genetics, Inc.
About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound (TNP). The company recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the Company) to license technology developed by M. Karen Newell, PhD that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. TNP may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. VGV-1 has been studied in five human clinical trials for the treatment of HIV / AIDS. Online at www.viralgenetics. com
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
Haig Keledjian, 626-334-5310